This week, a controversy was ignited after Turing Pharmaceuticals chief executive Martin Shkreli hiked the price for his drug Daraprim by 4,000 percent. Aaron Kesselheim, associate professor of medicine at Brigham and Women's Hospital, is quoted.
News & Research
